Noveome Biotherapeutics Inc.

03/27/2026

https://www.einpresswire.com/article/901954254/noveome-biotherapeutics-announces-positive-data-safety-monitoring-board-recommendation-in-ongoing-nec-clinical-trial

We are pleased to share this exciting next step in our clinical trial. The independent Data Safety Monitoring Board (DSMB) has completed its review of safety data from Cohort 1 of the ongoing clinical trial evaluating ST266 for the treatment of necrotizing enterocolitis (NEC) in neonates. The DSMB recommended that the study continue without modifications, noting no safety concerns in any of the infants treated with ST266 in the first Cohort of this groundbreaking trial. Thank you to our hard-working team and all of the clinical sites working on this trial.

09/16/2025

Noveome was honored to participate in the NEC Society Conference this past week! It was truly inspiring to connect with researchers, clinicians, and parents who share the same deep dedication we do—building a world without NEC.

09/15/2025

Noveome's Chief Medical Officer, Dr. Karin Potoka, presented at the NEC Society symposium in Chicago about the possibilities of treating this devastating disease. One baby dies of NEC in America every day. We are enrolling in a Phase 1/2 clinical trial for the treatment of NEC with a novel secretome, ST266. Find out more at clinicaltrials.gov

08/28/2025

We are excited to share that our Chief Medical Officer, Dr. Karin Potoka will be speaking at the NEC Symposium in Chicago. Dr. Potoka will share information about the potential benefits of our ST266 in the treatment of NEC.

The NEC Symposium in Chicago, presented by the NEC Society, Cincinnati Children’s, and UNC Children’s, is the world’s largest scientific meeting dedicated to necrotizing enterocolitis (NEC).

’s session on Promising Treatments for NEC will explore promising treatment options for NEC and strategies to build a world without this cruel disease through research and innovation. Cassandra Oliger will open the session by sharing the story of her daughter, Nora, who tragically passed away from NEC.

During this session, you will hear from key leaders in the field:

✔️ Eric Benner, MD, PhD – Duke University School of Medicine
✔️ Gail Besner, MD, FACS, FAAP – Nationwide Children’s Hospital
✔️ David Hackam, MD, PhD – Johns Hopkins Children’s Center
✔️ Karin Potoka, MD, FAAP – Noveome Biotherapeutics, Akron Children’s

Current options to treat and are inadequate - collaboration and dialogue at are crucial to advancing NEC research, education, and advocacy.

The Promising Treatments for NEC session will be moderated by David Russell, JD, Director of Research at Cincinnati Children’s and father of a child who survived NEC in the NICU.

Join us for the NEC Symposium in Chicago, happening September 7–10, 2025: NECsociety.org/NEC-Symposium

04/23/2025

We are pleased to announce the completion of our Series E financing round. The funds will be used to support financing our Clinical Trial in NEC. Necrotizing Enterocolitis (NEC) is a devastating disease, affecting thousands of pre-mature infants, with a 30% mortality rate.

The financing will be primarily used to support the advancement of the Company’s clinical stage program for the treatment of Necrotizing Enterocolitis

11/20/2024

https://www.einpresswire.com/article/762021979/noveome-biotherapeutics-announces-issuance-of-u-s-patent-no-12-121-546-treatment-of-systemic-inflammatory-responses

Another big day for Noveome Biotherapeutics, Inc., as we have added to our patent portfolio. We are currently running a clinical trial to treat NEC, one of many devastating diseases involving systemic inflammatory response.

11/14/2024

https://www.einpresswire.com/article-print/760713709/noveome-biotherapeutics-completes-dosing-of-first-baby-in-clinical-trial-for-treatment-of-necrotizing-enterocolitis

Today, Noveome announced that it has completed treatment of the first baby in its Phase 1-2 clinical trial evaluating the safety and efficacy of its novel biologic ST266 in Necrotizing Enterocolitis (NEC). To say we are excited is a complete understatement. So proud of the entire Noveome team.

12/11/2023

https://www.einpresswire.com/article/674369015/noveome-biotherapeutics-inc-receives-fda-notification-to-proceed-with-its-phase-1-2-clinical-trial-in-treatment-of-nec

Huge day for Noveome Biotherapeutics Inc.! We are pleased to announce that the company received notification from the FDA, to proceed with our Clinical Trial , evaluating ST266 in the treatment of Necrotizing Enterocolitis(NEC) in Premature infants. We are so excited to get the Clinical Trial underway and potentially provide the first breakthrough treatment in over 30 years.

08/17/2023

https://www.einpresswire.com/article/650523016/noveome-biotherapeutics-inc-completes-first-close-of-40-million-series-e-financing-to-support-clinical-trials-in-nec

We are excited to announce the first close of Series E Financing. This investment will be used to move forward on a clinical trial in Necrotizing Enterocolitis, a devastating disease that affects pre-mature infants. Our Pre-Clinical data looks promising and suggests that ST-266 may be effective in both preventing and treating NEC.

05/12/2023

Our Chief Scientific Officer, Larry Brown, ScD had the opportunity to give a presentation on the years of research and development as well as the many healing possibilities of our Novel Secretome ST-266. We are so proud of the work by our team in the past, and looking forward to the future impact on patients.

Noveome Biotherapeutics, Inc., a clinical-stage biopharmaceutical company located in Bridgeside, the premier hub for bustling life sciences and research activity in Pittsburgh, is making groundbreaking strides in their efforts to transform the way challenging diseases and conditions are treated. To

11/16/2022

Noveome Biotherapeutics, Inc., a clinical stage biopharmaceutical company focused on developing next-generation biologics for the restoration of cellu

11/16/2022

https://www.businesswire.com/news/home/20221116005292/en/Noveome-Biotherapeutics-Inc.-Announces-New-Appointments-to-Board-of-Directors

We are excited to announce the appointment of two new members to our Board of Directors. Both bring a wealth of knowledge and experience to help advance the development of ST266. Welcome Eric and Houman!

Noveome Biotherapeutics, Inc., a clinical stage biopharmaceutical company focused on developing next-generation biologics for the restoration of cellu